← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 150 mg every two weeks or 300 mg every four weeks as IV monotherapy for adults with unresectable or metastatic ESCC previously treated with systemic chemotherapy without a PD-1 or PD-L1 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The additional intervals offer scheduling alternatives for the existing post-chemotherapy monotherapy use.

What research teams should watch

Record prior checkpoint exposure and select the regimen interval before scheduling infusion and assessment visits.

PRIMARY RECORDS

Sources